Racura featured in Stockhead’s Investor Guide: Health & Biotech FY25

Racura is pleased to be featured in Stockhead’s Investor Guide this year. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors.

In this feature, Racura CEO Dr Daniel Tillett shares the company’s journey of discovering and developing lead asset bisantrene, a unique drug for its anticancer and cardioprotective properties. Dr Tillett also notes that the company is well positioned financially for its clinical pipeline.

You can read the complete guide via this link.